FeesSafety
Pluang+

Johnson & Johnson preferred over Procter & Gamble for 20-year dividend growth potential.

Analyst Insights
06 Oct 2026, 14:30 WIB
24/7 Wall Street
View Source
Bullish
Johnson & Johnson preferred over Procter & Gamble for 20-year dividend growth potential.

Johnson & Johnson and Procter & Gamble are both Dividend Kings with similar valuations, but Johnson & Johnson is favored for long-term dividend growth due to better dividend coverage, lower payout ratio, and stronger growth prospects despite P&G's longer dividend history and higher yield. J&J’s diversified product growth and lower structural risks position it to raise dividends more sustainably over 20 years. Investors should watch J&J’s litigation costs and upcoming business changes, but its recent performance and management guidance suggest a stronger dividend profile than P&G for long-term retirees.

Johnson & Johnson trades at USD 253.93 with a 0.40% gain as of Oct 06, 2026 18:44 WIB on Pluang. Procter & Gamble is priced at USD 147.92, up 1.36% at the same time. Despite P&G's higher dividend yield of 2.98%, J&J's market cap of $609.54B is nearly double P&G's $338.97B, showing stronger market confidence in J&J's growth prospects.

More News (JNJ)

Johnson & Johnson remains a strong dividend stock but trades at a premium valuation.

Johnson & Johnson remains a strong dividend stock but trades at a premium valuation.

Johnson & Johnson continues to show resilience with a 64-year dividend increase streak and raised full-year revenue and earnings guidance for 2026. Despite its strong business fundamentals and leadership in pharmaceuticals and medical devices, the st...

Company Fundamentals
Bullish
6 hours ago
Johnson & Johnson favored over Pfizer for steady growth and dividend in 2027 healthcare sector race

Johnson & Johnson favored over Pfizer for steady growth and dividend in 2027 healthcare sector race

Johnson & Johnson and Pfizer are key healthcare giants with differing strategies: J&J balances drug innovation and medical devices, while Pfizer focuses on oncology and obesity treatments. J&J reported stronger revenue growth and higher net income, w...

Market News
Neutral
7 hours ago
Johnson & Johnson remains a strong dividend stock but is pricey for value investors now.

Johnson & Johnson remains a strong dividend stock but is pricey for value investors now.

Johnson & Johnson continues to lead in pharmaceuticals and medical devices, boasting a 64-year streak of dividend increases. The company recently raised its full-year revenue and earnings guidance, reflecting solid business performance. However, its ...

Company Fundamentals
Bullish
11 hours ago
Johnson & Johnson favored over Pfizer for steady growth and dividend in 2027 healthcare sector race

Johnson & Johnson favored over Pfizer for steady growth and dividend in 2027 healthcare sector race

Johnson & Johnson and Pfizer, two healthcare giants, are taking different growth paths heading into 2027. Johnson & Johnson maintains a balanced business with strong pharmaceutical and medical device segments, showing steady revenue growth and a soli...

Market News
Neutral
12 hours ago
Dow drops nearly 950 points into correction as tech sell-off spreads and Fed rate hike looms

Dow drops nearly 950 points into correction as tech sell-off spreads and Fed rate hike looms

The Dow Jones Industrial Average fell nearly 950 points on Friday, entering correction territory by closing over 10% below its record high. The sell-off was driven by continued weakness in technology stocks, including a 14% drop in Nvidia after SEC a...

Bearish
15 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App